Home
>
US Stocks
>
VBI Vaccines Inc.
VBI Vaccines Inc.
VBIV

VBI Vaccines Inc. (VBIV)

$3.0410.32%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
3.11
Today Low/High
3.04 / 3.12
52 Week Low/High
$2.07 / $5.2
P/E ratio
-11.6144
Market Cap
$737.3M

Company Details

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel under the name Sci-B-Vac® and completed its Phase 3 program in the U.S., Europe, and Canada in 2020; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.
Organisation
VBI Vaccines Inc.
Employees
130
Industry
Health Technology

Discover more

Frequently Asked Questions

What is VBI Vaccines Inc. (VBIV) share price today?

Can Indians buy VBI Vaccines Inc. (VBIV) shares?

How can I buy VBI Vaccines Inc. (VBIV) shares from India?

Can Fractional shares of VBI Vaccines Inc. (VBIV) be purchased?

What are the documents required to start investing in VBI Vaccines Inc. (VBIV) stocks?

We are a SEBI registered investement advisor